PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
153.33%
Revenue growth above 20% – Exceptional top-line expansion. Warren Buffett would check if rising costs (e.g., SG&A) are still under control, ensuring profits grow alongside sales.
73.30%
Gross profit growth above 20% – Exceptional. Warren Buffett would verify if increasing margins accompany rising gross profit, not just revenue volume.
-15.23%
Negative EBIT growth points to weakening core profitability. Benjamin Graham would question management efficiency.
-15.23%
Negative operating income growth means rising costs or falling revenues are eroding core profitability. Benjamin Graham would raise caution.
-9.33%
Negative net income growth shows profitability erosion. Benjamin Graham would worry about solvency and longer-term viability.
-5.41%
Negative EPS growth underscores deteriorating earnings per share. Benjamin Graham would worry about ongoing dilution or weakened profitability.
-8.33%
Negative diluted EPS growth suggests diluted shares grew or net income fell. Benjamin Graham would see this as a serious setback to shareholder value.
2.98%
Share count up to +3% – Slight dilution. Howard Marks would be cautious but might accept it if used for profitable growth investments.
2.03%
Diluted share count up to +3% – Modest dilution. Howard Marks might tolerate it if used for high-ROI projects or strategic acquisitions.
No Data
No Data available this quarter, please select a different quarter.
-36.10%
Negative OCF growth is a critical warning sign. Benjamin Graham would check if receivables are ballooning or if core sales are declining.
-34.66%
Negative FCF growth reveals potential liquidity pressures or large capex overshadowing cash generation. Benjamin Graham would demand deeper scrutiny.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
95.84%
10Y OCF/share CAGR above 15% – Outstanding long-term cash-generation growth. Warren Buffett would check if reinvestment needs remain manageable.
71.82%
5Y OCF/share CAGR above 15% – Very robust mid-term cash expansion. Warren Buffett would check if reinvestment fosters sustainable growth.
66.77%
3Y OCF/share CAGR above 15% – Rapid short-term expansion. Warren Buffett would see if this stems from genuine operational improvements vs. working-capital swings.
96.67%
10Y net income/share CAGR above 15% – Exceptional long-term profit growth. Benjamin Graham would confirm if these gains hold through economic cycles.
77.76%
5Y net income/share CAGR above 15% – Strong mid-term profit growth. Benjamin Graham would check if leverage artificially boosts earnings.
53.48%
3Y net income/share CAGR above 15% – Rapid short-term profit growth. Benjamin Graham would verify if it’s driven by core revenue or temporary cost reductions.
61.16%
10Y equity/share CAGR above 12% – Excellent long-term book value compounding. Warren Buffett would see if consistent profits plus moderate payouts drive this growth.
-44.17%
Negative 5Y equity/share CAGR suggests net worth destruction. Benjamin Graham would see if failing profitability or large payouts cause it.
152.11%
3Y equity/share CAGR above 12% – Excellent recent net worth expansion. Warren Buffett would check consistent earnings retention or beneficial buybacks driving this growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
A negative 3Y dividend/share CAGR suggests recent cuts. Benjamin Graham confirms if a short-term profit dip or strategic pivot caused them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
Negative asset growth may reflect divestitures or depreciation outpacing new investments. Benjamin Graham wonders if shedding non-core assets improves focus or signals trouble.
-9.40%
Falling book value/share indicates net losses, large dividends, or intangible impairments. Benjamin Graham warns unless there’s a strategic reason.
-0.77%
A negative growth rate in debt means deleveraging, often positive for conservative investors. Benjamin Graham confirms it doesn’t restrict needed investments.
8.30%
R&D growth 0-10% – Balanced approach. Seth Klarman sees manageable cost if new products are still in development.
28.80%
SG&A growth above 15% – Aggressive expense expansion. Philip Fisher demands a compelling ROI argument for such heavy spending.